CCM
DGX icon

Chilton Capital Management’s Quest Diagnostics DGX Stock Holding History

Chilton Capital Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-21
Closed -$3.26K – 586
2024
Q3 		$3.26K Buy
+21
New +$3.14K ﹤0.01% 568
2023
Q3 		– Sell
-200
Closed -$28.1K – 522
2023
Q2 		$28.1K Hold
200
– – ﹤0.01% 376
2023
Q1 		$28.3K Buy
+200
New +$28.6K ﹤0.01% 384
2022
Q3 		– Sell
-270
Closed -$36K – 309
2022
Q2 		$36K Buy
+270
New +$36.8K ﹤0.01% 348
2022
Q1 		– Sell
-300
Closed -$52K – 313
2021
Q4 		$52K Buy
+300
New +$45.6K ﹤0.01% 331

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $23.3B AUM 26.95% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $44.4B AUM 36.05% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Chilton Capital Management's DGX Position: Q4 2024 in Review

Chilton Capital Management sold out of Quest Diagnostics (DGX) in Q4 2024, closing a stake of 21 shares — an estimated $3.26K sold.

Chilton Capital Management first reported a position in DGX in Q4 2021 and held it in 5 quarters. The position peaked at $52K in Q4 2021. 897 funds tracked by Wall St. Rank hold DGX as of Q4 2024.

  • Chilton Capital Management reported no remaining Quest Diagnostics position as of Q4 2024 after selling out during the quarter.
  • Chilton Capital Management sold 21 Quest Diagnostics shares in Q4 2024, an estimated $3.26K.
  • Chilton Capital Management first reported a position in Quest Diagnostics in Q4 2021 and held it in 5 quarters.
  • Chilton Capital Management's Quest Diagnostics position peaked at $52K in Q4 2021.
  • 897 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2024.

Based on Chilton Capital Management's 13F filing for Q4 2024, filed 7 Feb 2025.